BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 28, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MGCD265: Preliminary Phase II data

MethylGene reported preliminary data from the 2-part, open-label, dose-escalation Phase II Trial 103 trial evaluating ascending doses of once-daily oral MGCD256 for 21 days in combination with either Tarceva erlotinib or Taxotere docetaxel. In 4 patients with metastatic stage IV NSCLC, MGCD265 plus Taxotere led...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >